Cardiovascular Risk in Type 2 Diabetic Patients With Asymptomatic Hyperuricemia and Gout

Código QR

Cardiovascular Risk in Type 2 Diabetic Patients With Asymptomatic Hyperuricemia and Gout

Aim: To study the differences in cardiovascular risk between type 2 diabetic and non-diabetic patients with asymptomatic hyperuricemia and gout using the Framingham Risk Score (FRS) and complex multimodal ultrasonography.

Guardado en:

Detalles Bibliográficos
Autores principales:	Gancheva R., Kundurdjiev A., Kundurdjiev T., Kolarov Zl.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2019
Materias:	cardiovascular risk type 2 diabetes asymptomatic hyperuricemia tophi Medicine R
Acceso en línea:	https://doaj.org/article/7c70e2637a4f47d7b64054857482709b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
por: Yousuf Waheed, et al.
Publicado: (2021)

Management of hyperuricemia in gout: focus on febuxostat
por: Mattheus K Reinders, et al.
Publicado: (2010)

Hyperuricemia as a Risk Factor for Cardiovascular Diseases
por: Ichiro Hisatome, et al.
Publicado: (2020)

Vascular Age as a Cardiovascular Risk Marker in Asymptomatic Patients with Type 2 Diabetes
por: Palma CCSSV, et al.
Publicado: (2020)

Prevalence and Determinants of Hyperuricemia in Type 2 Diabetes Mellitus Patients Attending Jimma Medical Center, Southwestern Ethiopia, 2019
por: Arersa KK, et al.
Publicado: (2020)

Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians
por: Han QX, et al.
Publicado: (2019)

Serum Oxidative Stress Markers are not Associated with Renal and Common Carotid Arteries Arteriosclerotic Vascular Changes in Patients with Gout
por: Gancheva R., et al.
Publicado: (2019)

Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?
por: Kim GH, et al.
Publicado: (2015)

Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications
por: Ke Si, et al.
Publicado: (2021)

Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
por: Vladimir V. Salukhov, et al.
Publicado: (2018)

Asymptomatic Hyperuricemia and Metabolically Unhealthy Obesity: A Cross-Sectional Analysis in the Tianning Cohort
por: Yu J, et al.
Publicado: (2021)

Association Between the Cardiometabolic Index and Hyperuricemia in an Asymptomatic Population with Normal Body Mass Index
por: Zuo YQ, et al.
Publicado: (2021)

The Clinical Effects of Febuxostat Alone or Combined with Arthroscopic Surgery for Gout: A Single-Center Retrospective Study
por: Gong Z, et al.
Publicado: (2021)

Partial Clinical Remission Reduces Lipid-Based Cardiovascular Risk in Adult Patients With Type 1 Diabetes
por: Benjamin Udoka Nwosu, et al.
Publicado: (2021)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Flow-mediated dilation can be used to predict incident hypertension in patients with hyperuricemia
por: Chunli Han, et al.
Publicado: (2019)

DIAGNOSTIC ACCURACY OF FIRST TRIMESTER HYPERURICEMIA FOR PREDICTION OF GESTATIONAL DIABETES MELLITUS
por: Aiza Rehman, et al.
Publicado: (2020)

FREQUENCY OF HYPERURICEMIA IN PATIENTS WITH CORONARY ARTERY DISEASE AND ITS ASSOCIATION WITH DISEASE SEVERITY, AGE, GENDER, DIABETES MELLITUS, AND HYPERTENSION
por: Syed Ahmad Raza, et al.
Publicado: (2021)

Attainment of recommended therapeutic targets of modifiable cardiovascular risk factors among individuals with type 2 diabetes mellitus screened at a diabetes clinic in Sri Lanka
por: Weerarathna TP, et al.
Publicado: (2018)

Pathophysiology of hyperuricemia and its clinical significance – a narrative review
por: Marta Skoczyńska, et al.
Publicado: (2020)

Disseminated gouty panniculitis: an unusual presentation of extensive cutaneous tophi
por: Penvadee Pattanaprichakul, et al.
Publicado: (2014)

Obesity Measures as Predictors of Type 2 Diabetes and Cardiovascular Diseases among the Jordanian Population: A Cross-Sectional Study
por: Hana Alkhalidy, et al.
Publicado: (2021)

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
por: Hinnen D, et al.
Publicado: (2019)

Nomogram for the Prediction of Intrahospital Mortality Risk of Patients with ST-Segment Elevation Myocardial Infarction Complicated with Hyperuricemia: A Multicenter Retrospective Study
por: Bai Z, et al.
Publicado: (2021)

Anthropometric Measurements, Metabolic Profile and Physical Fitness in a Sample of Spanish Women with Type 2 Diabetes
por: María Orosia Lucha-López, et al.
Publicado: (2021)

Audio-Vestibular Findings in Patients with Hyperuricemia
por: Mohamed Mahmoud Al-Sobki, et al.
Publicado: (2020)

Relationship Between Skeletal Muscle Mass to Visceral Fat Area Ratio and Cardiovascular Risk in Type 2 Diabetes
por: Liu D, et al.
Publicado: (2021)

Dose–Response Relationship Between BMI and Hyperuricemia
por: Yang L, et al.
Publicado: (2021)

FREQUENCY OF HYPERURICEMIA IN HYPERTENSIVE PATIENTS AND ITS ASSOCIATION WITH AGE OF PATIENT
por: Syed Saif Ul Hassan Shah, et al.
Publicado: (2021)

Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
por: Gong M, et al.
Publicado: (2020)

Asymptomatic Shedding of Respiratory Virus among an Ambulatory Population across Seasons
por: Ruthie Birger, et al.
Publicado: (2018)

Type 2 diabetes and psoriasis: links and risks
por: Holm JG, et al.
Publicado: (2019)

Value of addition of coronary artery calcium to risk scores in the prediction of major cardiovascular events in patients with type 2 diabetes
por: Barak Zafrir, et al.
Publicado: (2021)

Blackcurrant Improves Diabetic Cardiovascular Dysfunction by Reducing Inflammatory Cytokines in Type 2 Diabetes Mellitus Mice
por: Hye-Yoom Kim, et al.
Publicado: (2021)

Sociodemographic and anthropometric risk factors for type 2 diabetes (T2D) in Nador population
por: Kenfaoui Ikram, et al.
Publicado: (2021)

Initial glucose-lowering therapy and risks of overall and cardiovascular mortality, myocardial infarction and stroke in patients with type2 diabetes
por: Inna Vladimirovna Misnikova, et al.
Publicado: (2009)

Heart-type fatty acid binding protein levels in elderly diabetics without known cardiovascular disease
por: Beysel S, et al.
Publicado: (2017)

Kolaviron attenuates cardiovascular injury in fructose-streptozotocin induced type-2 diabetic male rats by reducing oxidative stress, inflammation, and improving cardiovascular risk markers
por: Jeffrey O. Adoga, et al.
Publicado: (2021)

Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form
por: Annа Malkova, et al.
Publicado: (2021)

Association of asymptomatic target organ damage with secreted frizzled related protein 5 in the elderly: the Northern Shanghai Study
por: Teliewubai J, et al.
Publicado: (2018)